bluuebunny/crossref_metadata_2025 huggingface dataset:
Reappraising the role of baseline plasma C-reactive protein levels on recurrence after catheter ablation of persistent atrial fibrillation: insight from EARNEST-PVI trial
Authors: Okada M , Inoue K , Tanaka N , Masuda M , Furukawa Y , Hirata A , Egami Y , Watanabe T , Minamiguchi H , Miyoshi M , Sunaga A , Sotomi Y , Dohi T , Hikoso S , Sakata Y
Published: October 2021

Background

Subclinical inflammation is an important pathogenesis of developing and sustaining atrial fibrillation (AF). Because AF itself contribute to the inflammatory response, the role of baseline subclinical inflammation on AF recurrence after catheter ablation (CA) remains controversial in patients with persistent AF.

Purpose

To evaluate whether baseline plasma C-reactive protein (CRP) levels, a sensitive marker of inflammation, are associated with AF recurrence following CA.

Methods

The analysis was performed from the EARNEST-PVI trial, a randomized controlled trial designed to assess a CA strategy for persistent AF, which was conducted in the Osaka region of Japan. A total of 441 patients (median age, 67 years; 26% female; 25% long-standing persistent AF) whose plasma CRP levels were measured at baseline were included in this study.

Results

At baseline, a median (interquartile range) of plasma CRP level was 0.10 [0.06–0.19] mg/dl. Plasma CRP levels significantly increased at discharge (0.83 [0.21–1.84] mg/dl, p<0.001) and decreased 1 year after CA (0.10 [0.05–0.20] mg/dl, p=0.040) compared to the baseline value. During the follow-up of 1 year, 115 patients (26%) experienced AF recurrence, and the incidence was significantly higher in 124 patients with low CRP levels at baseline (cut-off ≤0.06 mg/dl) than the other 317 patients (33.9% vs. 23.0%, p=0.017). After adjustment of age, gender, body mass index, long-standing persistent AF, CA strategy, and plasma brain natriuretic peptide levels, low plasma CRP levels was a significant predictor of AF recurrence (hazard ratio, 1.51; 95% confidence interval, 1.02–2.24; p=0.042).

Conclusions

Low plasma CRP levels at baseline predicted AF recurrence in the EARNEST-PVI trial. Reappraising the role of CRP on AF recurrence may be needed in patients with persistent AF.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): Johnson & Johnson KK
Incidence of left atrial appendage thrombus on pre-procedural TOE before catheter ablation of atrial tachyarrhythmias
Authors: Wegner F , Radke R , Ellermann C , Wolfes J , Fischer A.J , Baumgartner H , Eckardt L , Diller G.P , Orwat S
Published: October 2021

Introduction

Transoesophageal echocardiography (TOE) is routinely performed before catheter ablation of atrial tachyarrhythmias to rule out the presence of possible left atrial thrombi. However, data to support this practice are scarce.

Methods

We analysed consecutive pre-procedural TOE in a high-volume electrophysiology centre for the presence of left atrial thrombi and a relevant flow reduction in the left atrial appendage (LAA) defined as LAA sludge or pronounced spontaneous echo contrast. Possible predictors of reduced flow were recorded and compared in a multivariate logistic regression analysis.

Results

1676 consecutive TOE were included (1122 before pulmonary vein isolation (PVI), 436 before atrial flutter ablation, 166 before other EP studies in patients with a history of atrial tachyarrhythmias). 543 patients (32%) were female, mean age was 63±12 years and BMI was 27±5 kg/m2. Nine patients (0.5%) had an LAA thrombus on pre-procedural TOE. Ninety-five further patients (5.7%) had a relevant reduction in LAA flow as characterized by LAA sludge or spontaneous echo contrast. Further patient characteristics by LAA flow state are shown in the table. While a higher CHA2DS2-VaSc-Score was associated with the presence of LAA sludge and LAA thrombus (p=0.01), no further clinical parameters such as choice of oral anticoagulation agent were independently predictive of reduced flow velocities or thrombus in a logistic regression model (see table). Importantly, LAA thrombi also occurred in patients with a CHA2DS2-VaSc-Score ≤1 (n=1) or in sinus rhythm (n=2). Of note, 6 out of 9 patients with a LAA thrombus were anticoagulated with phenprocoumon.

Conclusion

LAA thrombus is a rare occurrence before an elective catheter ablation. In patients with CHA2DS2-VaSc-Score ≤1 the likelihood of LAA thrombus is so low (0.2%) that it may be considered to give up routine TOE before an EP study/ablation.

Funding Acknowledgement

Type of funding sources: None.
Low incidence of major complications after the first six hours post-atrial fibrillation ablation – same-day discharge safe and feasible in most patients
Authors: Paul Nordin A , Drca N , Insulander P , Bastani H , Bourke T , Braunschweig F , Kenneback G , Von Olshausen G , Sadigh B , Saluveer O , Tapanainen J , Schwieler J , Akerstrom F , Jensen-Urstad M
Published: October 2021

Background/Introduction

Catheter ablation of atrial fibrillation (AF) is associated with a complication risk. It is common practice to monitor patients overnight post-procedurally which is resource craving.

Purpose

To evaluate the incidence of procedural complications related to catheter ablation of AF to assess the potential feasibility and safety of same day discharge in a large cohort.

Methods

We performed an analysis of prospectively collected data of complications of all patients staying overnight after undergoing AF ablation between 2001 and 2020 at a tertiary centre. By studying medical records, we analysed complications occurring intraprocedurally until six hours post-ablation, and between six hours post-ablation until discharge the day after ablation procedure (up to 24 hours post-procedure).

Results

In 5414 AF ablations we identified a total of 108 (2.0%) major complications occurring intraprocedural or until discharge the day after procedure. Most major complications occurred early and were detected intraprocedurally or within six hours after completed procedure (n=96, 1.8%). Twelve (0.2%) major complications occurred between six hours post-ablation and until discharge the day after procedure. The most common of these were congestive heart failure (n=6) and transient ischemic attack (TIA, n=4). In addition, there were 61 (1.1%) minor complications which occurred in this time span. Factors independently associated with major complications intraprocedurally or within 24 hours were age (p=0.046), body mass index (BMI) ≥30 kg/m2 (p=0.009), significant valvular disease (p=0.001), cardiomyopathy (p<0.001), prior stroke or TIA (p=0.014), first time procedure vs. repeat procedure (p=0.013), cryoablation vs. radiofrequency (p<0.001) and procedure duration (p<0.001).

Conclusion

Very few complications occurred between six hours and until discharge after ablation of atrial fibrillation. Therefore, same-day discharge may be a safe option for a large proportion of patients.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Region Stockholm funding
Fully automated left ventricular ejection fraction and global longitudinal strain predicts obstructive coronary artery disease in patients undergoing stress echocardiography: a multi-centre study
Authors: O'Driscoll J , Hawkes W , Beqiri A , Mumith A , Parker A , Upton R , McCourt A , Woodward W , Dockerill C , Heitner S , Yadava M , Kaul S , Sharma R , Leeson P , Woodward G
Published: October 2021

Background

Assessment of LVEF and myocardial deformation with GLS has shown promise in predicting CAD, which may add prognostic information for patients undergoing SE. However, selection bias precludes an accurate assessment of routine clinical SE workflow due to the exclusion of poor image quality and contrast enhanced studies. We hypothesise that an artificial intelligence (AI) pipeline capable of fully automated contouring of the left ventricle and GLS analysis of both non-contrast and contrast SE images is feasible and can predict CAD.

Purpose

The aim of this study was to evaluate the prediction of obstructive coronary artery disease (CAD) from fully automated left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) measures in a large multicentre population of patients undergoing stress echocardiography (SE).

Methods

500 patients from five medical centres undergoing SE for the clinical evaluation of ischaemic heart disease were included in this study. LVEF and GLS was automatically calculated using AI in non-contrast and contrast images at rest and peak stress. The primary endpoint was CAD assessed using invasive coronary angiography.

Results

Patients with significant CAD demonstrated significantly reduced LVEF and GLS at rest and peak stress (all p<0.001) compared to those without CAD. Of the 130 patients who exhibited myocardial ischaemia at peak stress, patients without significant CAD (37%) had significantly reduced LVEF and GLS when compared to those who did. Multivariate analysis demonstrated that a peak LVEF (0.93; 95% CI 0.9–0.96) and peak GLS (1.15; 95% CI 1.07–1.24) were significant independent predictors of CAD. The addition of automated LVEF and GLS to basic models significantly improved the C statistic from 0.78 to 0.83 and 0.85 (both p<0.001), respectively.

Conclusions

Fully automated LVEF and GLS in non-contrast and contrast SE images is feasible and independently augment the prediction of obstructive CAD above and beyond traditional SE indexes.

Funding Acknowledgement

Type of funding sources: None.
Screening for anticoagulation undertreatment in more than 100,000 patients with atrial fibrillation in general practices in the Netherlands
Authors: Voorhout L.J , Pisters R , Geurts C.H.P.H , Oostindjer A , Van Doorn S , Rila H , Fuijkschot W.W , Hemels M.E
Published: October 2021

Background and aim

Atrial fibrillation (AF) is associated with a significant morbidity and increased mortality risk, predominantly due to risk of stroke and thromboembolism. Despite availability of highly effective and practical oral anticoagulation (OAC) guidelines recommended therapy is often underutilized. Therefore, we investigated the underuse of OAC in individual AF patients through on-demand screening of general practices (GPs) across the Netherlands.

Methods

We performed a multi-center, cross-sectional study in 39 GPs. Using electronic patient files, we were able to screen the entire GP population for AF, CHA2DS2-VASc scores, and the use of guidelines recommended OAC. In case of OAC undertreatment we checked for any documented reason. Additionally, six weeks following the screening we asked all GPs to provide information on actions taken for the undertreated patients.

Results

In total 101,207 patients records were screened identifying 2,375 non-valvular AF patients with a mean CHA2DS2-VASc score of 3.2. OAC use consisted of direct oral anticoagulants in 1,342/1,984 (68%) and vitamin K antagonists in the remainder of patients. OAC undertreatment was present in 92/1001 (9,2%) males and 102/1374 (7,4%) in females, respectively. Figure 1 shows the GP patient population with AF, divided into groups by CHA2DS2-VASc score and their corresponding antithrombotic therapies. Reasons to withhold OAC were patient refusal (n=10), cardiologist advice (n=7), high risk of bleeding (n=7), and terminal illness (n=4). In 159/194 (82%) patients no reason was reported. Data regarding actions following the identification of OAC undertreatment was available in 29 practices representing 92/194 (47%) of the OAC undertreatment cases. After consultation OAC was initiated in 9/92 (10%) only.

Conclusions

In this large Dutch study among GPs we observe 8.2% undertreatment of OAC in AF patients. More males than females were undertreated as were those with the highest CHA2DS2-VASc scores. Only in a small minority of cases detection of OAC undertreatment lead to OAC initiation. This highlights the need to improve awareness and communication of OAC treatment aimed at preventing strokes.

Funding Acknowledgement

Type of funding sources: None. Figure 1
Higher mortality in frail elderly with atrial fibrillation using oral anticoagulants
Authors: Walgers J.J , Zwart L.A.R , Simsek S , Germans T , Hemels M.E.W , Jansen R.W.M.M
Published: October 2021

Background/Introduction

Frail older persons with falls are often undertreated for atrial fibrillation (AF) due to fear of bleeding complications of oral anticoagulants (OAC). However, the safety of OAC use in frail elderly with AF and falls is not investigated extensively.

Purpose

The aim of the study was to investigate whether frail older persons with falls and OAC for AF have more bleeding complications than patients without OAC and to investigate the association between frailty, OAC therapy (including bleeding complications), and mortality.

Methods

This observational study included frail patients aged 65 years or older who were evaluated for falls between November 2011 and December 2019. Patients using OAC for AF were compared with similar patients without using OAC.

Primary outcomes were death, major bleeding and intracranial bleeding. Secondary outcomes were frailty measured by the Frailty Index and cause of death.

Results

Of the 645 included patients, 132 had AF and used OAC. Patients with AF were more often severely frail (67% vs. 47%, p<0.001) and had a higher mortality during follow up (39% vs. 27%, p=0.005). Patients using OAC had a higher mortality risk compared to the patients without OAC (crude analysis Hazard Ratio (HR) 1.7 (95% confidence interval (CI) 1.3–2.4), p=0.001; after adjustment for age, gender, and frailty index HR 1.4 (95% CI 0.99–1.9) p=0.056). No differences were found in the incidence of major bleedings (10% vs. 7%, p=0.204) or intracranial bleedings (5% vs. 4%, p=0.739) in both groups. The causes of death were similar in both groups, also the incidence of fatal bleedings did not differ (5% vs 7%, p=0.758).

Conclusions

Elderly with falls and AF using OAC are frailer and have a tendency to a higher mortality risk than patients without AF. These frail elderly patients with falls had no more bleeding complications during OAC treatment than comparable patients without OAC. Therefore, withholding OAC out of fear for major bleeding complications is not justified.

It is unclear why elderly persons with AF and OAC are frailer and die sooner, since the incidence of major bleedings and fatal bleedings is equal. Further research should focus why older frail persons with AF are more prone to die.

Funding Acknowledgement

Type of funding sources: None.
Discontinuation of anticoagulation and its associated factors in atrial fibrillation
Authors: Sanchez Bustamante S , Navarro Estrada J.L , Rossi E , Gamarra A.L , Maid G.F , Pizarro R
Published: October 2021

Background/Introduction

Oral anticoagulation has been shown to reduce the incidence of embolic events associated with atrial fibrillation, however the discontinuation of these drugs observed in clinical trials may not be representative of the real-world setting due to the inclusion of selected populations.

Purpose

The objective of the study was to compare whether there is a difference in the incidence rate of discontinuation between vitamin K antagonists and direct anticoagulants and to evaluate the factors associated with non-adherence in patients newly diagnosed with atrial fibrillation.

Methods

This was a prospective cohort study. Adult patients (age >18 years) who had newly started anticoagulation therapy for atrial fibrillation or atrial flutter were enrolled. Patients with previous oral anticoagulation, mechanical prosthetic heart valves or creatinine clearance less than 30 mL/min were excluded. The follow-up period was 12 months. As the treatment allocation was not randomized, a propensity score weighting was performed considering baseline characteristics potentially associated with exposure and outcome. Factors associated with anticoagulant discontinuation were evaluated using a weighted Cox model.

Results

A total of 379 patients were included (mean age 78±9 years, 58% females). The median follow-up was 362 days (IQR 347–370). Loss to follow-up was 1%. The anticoagulation discontinuation rate was 24.6% in the direct anticoagulant group and 15.6% in the vitamin K antagonist group. A weighted model of time to discontinuation of anticoagulation treatment showed a crude HR of 1.40 (95% CI 0.79–2.48) for the direct anticoagulant therapy group compared to the vitamin K antagonist group, and a model adjusted for age, type of atrial fibrillation, radiofrequency ablation, bleeding, number of chronic drugs, and cardiology consultations during follow-up showed an adjusted HR of 1.26 (95% CI 0.75–2.12). The main reason for discontinuation of anticoagulation was high risk of bleeding in the vitamin K antagonist group and performance of a radiofrequency ablation procedure in the direct anticoagulant group. There was no statistically significant difference in the discontinuation rate between both groups when the baseline characteristics of the patients were considered.

Conclusion(s)

There was no statistically significant difference in the discontinuation rate between both groups when the baseline characteristics of the patients were considered.

The study showed that the discontinuation of anticoagulants in atrial fibrillation in our setting was not associated with the type of drug used, the age of patients, or the type of arrhythmia.

Funding Acknowledgement

Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Boehringer Ingelheim Figure 1
Non-vitamin K antagonist oral anticoagulant discontinuation in non-valvular atrial fibrillation patients (ASPECT-NOAC)
Authors: Asilturk E , Tulmac M , Badak Ö , Onal T , Aras D , Aciksari G , Alper A.T , Celik A , Katicibasi T , Ozdogan O ,   ASPECT-NOAC Study Investigators
Published: October 2021

Background and aim

Data on NOAC discontinuation patterns in Turkey are lacking. We conducted a subgroup analysis in ASPECT-NOAC study to determine anticoagulant discontinuation pattern in AF patients with recently initiated NOAC therapy.

Methods

ASPECT-NOAC was a national, multicenter, 12-month observational study conducted in 34 outpatient cardiology clinics of state, university, private, and research hospitals covering all geographic regions of Turkey. Adult AF patients who were under NOAC therapy for less than four months were enrolled. Patients who discontinued using their NOACs were recorded at the end of 12 months. A comparative analysis of patients with discontinuation of medication was conducted.

Results

This study included 991 non-valvular AF patients. NOAC continuation data were available for 854 patients. During study follow-up, 74 patients (8.7%) discontinued their NOAC medication. Mean age of these patients was 67.1±11.3 years old and 38 patients (51.4%) were female. Most commonly seen comorbidities were hypertension (66.2%) and coronary heart disease (39.2%). 29 patients (39.2%) had permanent (chronic) AF, followed by 26 patients (35.1%) with paroxysmal AF. Major reason for NOAC discontinuation was stated as physician request (n=46, 62%). Following reasons were patient request (n=17, 23%), other (n=9, 12%), and bleeding (n=2, 3%). Patients with NOAC discontinuation had a shorter duration of AF (21.7±41.7 vs 26.2±53.7 months, p=0.017). There was no significant difference of educational levels between medication discontinuation subgroups (p=0.637). Other baseline characteristics and patient disease and treatment awareness levels were similar with the patients who continued their medication. Of 74 patients, two patients died during the study because of cardiac failure.

Conclusion

NOAC continuity rate over 12 months was found to be high. NOAC discontinuation rate were higher in the patients with shorter duration of AF. Further studies with long-term follow-up detailing discontinuation reasons are warranted.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): This study was funded by Pfizer.
One year outcome and analysis of peri-device leak of left atrial appendage occlusion devices
Authors: Mansour M , Harnay E , Al Ayouby A , Mansourati V , Jobic Y , Gilard M , Le Ven F , Mansourati J
Published: October 2021

Background

The prevalence of peri-device leak (PDL) of left atrial appendage occlusion (LAAO) devices has been previously reported. However, there have been only few data that compared different existing devices. The aim of this study was to assess the incidence of PDL with both devices WATCHMAN® and AMPLAZER Amulet®, and to evaluate the clinical outcome at 12 months.

Methods

Consecutive patients who underwent LAAO between January 2018 and 2020 were randomly assigned to either WATCHMAN or AMPLATZER Amulet implantation based on a systematic two-week alternation between both devices. LAA measurements were assessed using cardiac computed tomography angiography (CCTA) prior to, and transesophageal echocardiography (TEE) during the procedure. At 8 weeks post-LAAO, patients underwent TEE and/or CCTA to identify the presence of PDL and/or device-related complications. Patients were then followed for 12 months to identify major adverse cardiovascular/embolic events.

Results

The cohort consisted of 51 patients (25 WATCHMAN, 26 AMPLATZER Amulet; mean age 76±7 years; male gender 76%). Both groups were identically matched for demographics, comorbidities and indication for LAAO. There were 19 patients who had PDL (13 WATCHMAN vs 6 AMPLATZER Amulet, P-value=0.033). Of them, 8 (15%) patients had significant PDL (7 WATCHMAN vs. 1 AMPLATZER Amulet, P-value=0.018). On CCTA, the landing zone maximal diameter of the AMPLATZER Amulet device had the strongest correlation with the final deployed device size (Spearman'rho 0.92, P-value<0.0001). In the multivariate analysis, male gender and device type were independent predictors of any PDL (P-values 0.016 and 0.031, respectively). On a mean follow-up of 12 months, the total number of events was more prevalent in the WATCHMAN group (P-value 0.008), but the incidence of cardio-embolic events reached borderline significance (16% vs. 0%, P-value=0.051).

Conclusions

Among patients who underwent LAAO, almost 15% had significant PDL with the majority belonging to the WATCHMAN group. Still, larger studies are warranted to evaluate its effectiveness in stroke prevention.

Funding Acknowledgement

Type of funding sources: None. Table 1Table 2
Role of oral flecainide in assessement of atrio-ventricular conduction in symptomatic bifascicular block
Authors: Kumar D , Dwivedi S.K , Chaudhary G , Sharma A , Chandra S , Vishwakarma P , Pradhan A , Sethi R , Bhandari M , Shukla A , Singh A
Published: October 2021

Background

Intravenous flecainide is used to stress Atrio-ventricular (AV) conduction in patients (pts) with a history of syncope & bifascicular (Bi-Fasc) block. Role of oral flecainide is unclear.

Objective

To assess effect of oral Flecainide on infra-Hisian AV conduction in patients with symptomatic Bi-Fasc block.

Methods

Pts presenting with syncope & Bi-Fasc block without advanced AVCD on ECG, 24 hr holter or treadmill exercise test were taken. Those with history suggestive of reflex syncope & positive tilt test were excluded. Remaining underwent electro-physiological (EP) study. Pts with HV interval >100ms or intra/infra-Hisian block at rest or incremental pacing were subjected to PPI. Remaining received oral Flacanide 5 mg/kg (max 300 mg) & EP study was repeated after ½ hr, 1 hr, 2 hrs and 3 hrs. Primary end-point was HV ≥100ms or infra/intra-Hisian type IIB or III block.

Results

Of 41 pts enrolled for study, 28 patients (mean age 60.0 yrs, mean LVEF 60.7%) were eligible for EP Study. Basal PR interval was 185.8±47.4 ms & mean QRS width was 130.6±18.65 ms. On EP study, 4 (14.3%) with resting HV >100 ms & 6 (21.4%) with HV >100 ms on incremental pacing underwent PPI.

Out of remaining 18 pts who were given flecainide, 11 (66.1%) achieved primary endpoint (HV >100 ms in 6, infra-hisian IIB in 2 and 2:1 block in 3 patients). At mean follow up of 6.5 months, 13 (59.1%) out of 22 with PPI had mean 59.1% VP & none of 6 remaining patients had any symptom.

Conclusion

Oral Flecainide significantly increases the diagnostic yield of EP study in patients with symptomatic bi-fasc block.

Funding Acknowledgement

Type of funding sources: None.
The relationship between anatomy and electrical parameters in His bundle pacing
Authors: Coluccia G , Senes J , Corallo S , Aste M , Oddone D , Donateo P , Puggioni E , Brignole M
Published: October 2021

Background

The relationship between anatomy and electrical parameters of His bundle (HB) pacing has not been extensively studied.

Purpose

To characterize the anatomical location of the HB lead tip and its relationship with acute electrical parameters.

Methods

Consecutive patients who underwent HB lead implantation, guided by standard fluoroscopy and electrophysiology, were prospectively enrolled. The relationship between HB lead tip and tricuspid valve plane (TVP) was assessed with post-procedure transthoracic echocardiography.

Results

Twenty-five patients were studied. In 11 patients (44%), the HB lead tip did not cross the TVP (A group): in 7 cases it was screwed in the right atrium at a mean distance of −6.1 mm from the TVP and, in 4 cases, at the level of the tricuspid annulus. In the remaining 14 patients (56%), the lead tip crossed the TVP (V group): it was screwed in the right ventricle at a mean distance of 9.3 mm from the TVP. A and V groups had comparable HB capture thresholds (1.6±1 V vs 1.7±0.7 V, 1 ms pulse-width; p=0.66); selective HB capture was significantly more represented in the A group (91% vs 21%; p=0.001). Significantly higher R-wave amplitudes were seen in the V group (6.7±3 vs 2.5±1.7 mV; p=0.0004), and they positively correlated with the distance from the TVP (p=0.0038). Atrial oversensing was never observed.

Conclusion

In a consecutive cohort of HBP recipients, the rate of patients who had an effective HB capture in the atrium was substantial and was characterized by different electrophysiological properties than in the ventricle.

Funding Acknowledgement

Type of funding sources: None.
COVID-19 patients present impaired endothelial glycocalyx, vascular dysfunction and myocardial deformation resembling those observed in hypertensives four months after infection
Authors: Ikonomidis I , Kountouri A , Mitrakou A , Thymis J , Katogiannis K , Korakas E , Varlamos C , Bamias A , Thomas K , Andeadou I , Tsoumani M , Kavatha D , Antoniadou A , Dimopoulos M.A , Lambadiari V
Published: October 2021

Background/Introduction

COVID-19 infection has been associated with increase arterial stiffness, endothelial dysfunction, and impairment in coronary and cardiac performance. Inflammation and oxidative stress have been suggested as possible pathophysiological mechanisms leading to vascular and endothelial deregulation after COVID-19 infection.

Purpose

The objective of our study is to evaluate premature alterations in arterial stiffness, endothelial, coronary, and myocardial function markers four months after SARS-CoV-2 infection.

Methods

We conducted a case-control prospective study, including 70 patients four months after COVID-19 infection, 70 age- and sex-matched untreated hypertensive patients (positive control) and 70 healthy individuals. We measured a) perfused boundary region (PBR) of the sublingual arterial microvessels (increased PBR indicates reduced endothelial glycocalyx thickness b) flow-mediated dilation (FMD), c) coronary Flow Reserve (CFR) by Doppler echocardiography d) pulse wave velocity (PWV) and central systolic (SBP) e) global LV longitudinal strain (GLS) by speckle tracking imaging and f) malondialdehyde (MDA) as oxidative stress marker.

Results

COVID-19 patients had similar CFR and FMD with hypertensives (2.48±0.41 vs 2.58±0.88, p=0.562, 5.86±2.82% vs 5.80±2.07%, p=0.872 respectively), but lower CFR and FMD than controls (3.42±0.65, p=0.0135 9.06±2.11%, p=0.002 respectively) Both COVID-19 and hypertensive group had greater PBR than controls (PBR5–25: 2.07±0.15 μm and 2.07±0.26 μm p=0.8 vs 1.89±0.17 μm, p=0.001). COVID-19 patients and hypertensives had higher PWV and central SBP than controls (PWVcf 12.09±2.50 and 11.92±2.94, p=0.7 vs 10.04±1.80 m/sec, p=0.036). COVID-19 patients and hypertensives had impaired values of GLS compared to controls (−19.50±2.56% and −19.23±2.67%, p=0.864 vs −21.98±1.51%, p=0.020). Increased PBR5–25 was associated with increased SBP central which in turn was related with impaired GLS (p<0.05). MDA was found increased in COVID-19 patients compared to both hypertensives and controls (10.67±2.75 vs 1.76±0.30, p=0.003 vs 1.01±0.50 nmole/L, p=0.001).

Conclusions

SARS-CoV-2 may cause impaired coronary microcirculatory, endothelial and vascular deregulation which remain four months after initial infection and are associated with reduced cardiac performance. The 10-fold increase of MDA compared to healthy individuals four months after COVID-19 infection indicate oxidative stress as possible pathophysiological mechanism.

Funding Acknowledgement

Type of funding sources: None.
Family screening in brugada syndrome patients
Authors: Cardoso A , Faria B , Von Hafe P , Dias G , Pereira T , Ribeiro S , Calvo L , Oliveira M , Fernandes M , Sanfins V , Lourenco A
Published: October 2021

Background

Brugada syndrome (BS) is a rare inherited channelopathy associated with sudden cardiac death (SCD) and family screening (FS) of index patients (pts) is recommended. However, data about pts identified through FS is lacking.

Aim

To compare index pts to non-index pts identified through systematic FS.

Methods

Single-center retrospective study of BS pts followed by the Arrhythmology Department. FS was offered to 1st degree relatives of all index pts through primary care services and a once-weekly voluntary open appointment. Genetic counselling was performed when indicated. Index and non-index pts were compared regarding baseline characteristics and events during the follow-up (syncope of probable arrhythmic origin, ventricular tachycardia/ventricular fibrillation (VT/VF) and SCD).

Results

We included 165 pts (61% males, mean age 47±15 years) and 72 (44%) were identified through FS. Non-index pts were diagnosed at a younger age (42±14 vs 51±14 years, p <.001), were more often female (57% vs 25%, p<.001), were diagnosed predominantly through provocative test with ajmaline/flecainide (88% vs 47%, p<.001) and had less documented spontaneous type 1 ECG pattern (17% vs 59%, p<.001). A type 2 pattern was identified in 18 (25%) non-index pts.

Genetic testing was performed in 38 (53%) non-index pts: 6 had a pathogenic SCN5A mutation, 18 a likely pathogenic SCN5A mutation and 12 a mutation of uncertain significance.

At diagnosis, 24 (33%) non-index pts had history of syncope, 3 (4%) had nocturnal agonal respiration and 11 (15%) had palpitations with no differences between both groups (p=.119). Non-index pts were less likely to implant a cardioverterdefibrillator (14% vs 38%, p=.001).

During a median follow-up of 28 (IQR 16–41) months, 10 (6%) pts had an event - 2 (3%) in the non-index group (2 syncope) and 8 (9%) in the index group (1 syncope; 7 VT/VF) - with no significative differences between groups (p=.432). There were nocardiovascular deaths.

Conclusions

FS identified a considerable proportion of BS pts. Non-index pts were younger at the time of the diagnosis and had less spontaneous type 1 pattern. No differences were found in events between index and non-index pts, however, the event rate was low. Systematic FS can identify individuals at risk of SCD earlier, allowing close monitoring and, when indicated, appropriate treatment.

Funding Acknowledgement

Type of funding sources: None.
Different response to vitamin D supplementation of PVCs from RVOT and non-outflow tract RV regions
Authors: Cismaru G , Tomoaia R , Minciuna I , Lazea C , Cainap S.S , Fringu F , Gurzau D , Rosu R , Gusetu G , Puiu M , Caloian B , Comsa D.H , Pop D , Zdrenghea D
Published: October 2021

Background

Recent publications have shown that premature ventricular contractions (PVCs)_ from the right ventricular outflow tract (RVOT) have a good response to vitamin D supplementation in patients that have a vitamin D deficiency.

Purpose

The present study aimed to compare the response to vitamin D supplementation of of 2 types of PVCs: from RVOT and from other RV areas outside RVOT

Methods

Our study included 16 patients from the Outpatient Clinic of the Rehabilitation Hospital, of whom all had vitamin D deficiency. Four patients had high PVC burden with an RV morphology other than RVOT and were matched 1:3 for age and sex with 12 patients with high PVC burden and RVOT morphology.

Results

Mean age was 26 years in both group and 33% were females. The mean 25-OH vitamin D value was 17.7±2.9 ng/ml in the non RVOT group and 21.6±5.3 ng/ml in the RVOT group. After 3±1.7 month of treatment with 2000–5000 U/day, 25 OH vitamin D increased to. 31.1±3.2. in the non-RVOT group and to 35.9±5.1 in the RVOT group. After treatment PVC burden decreased from 19956±2618 to 19399±3015 (NS) in the non-RVOT group and from 21057±9594 to 4249±2835 (p=0.0001) in the RVOT group.

Conclusions

After 3 months of vitamin D supplementation in patients with high burden PVC and vitamin D deficiency, the burden decreased significantly by more than 75% in the RVOT morphology group but not in the non- RVOT morphology group.

Funding Acknowledgement

Type of funding sources: None. PVC burden in the non RVOT groupPVC burden in the RVOT group
Non-invasive mapping reduces procedure duration for catheter ablation of premature ventricular contractions using 12 lead ECG information: results from a prospective case-control study
Authors: Griffiths J , Cazzoli I , Ailoaei S , Guarguaglia S , Kempny A , Ernst S
Published: October 2021

Background

Premature ventricular complexes (PVCs) result from early depolarisation of myocardial tissue in the ventricles and can ultimately lead to PVC-induced cardiomyopathy. Catheter ablation aims to completely eliminate the PVCs and is usually carried out using sequential activation mapping techniques. We report the results of a prospective case-control trial using the non-invasive, simultaneous 3D mapping system View into Ventricular Onset (VIVO) in combination with a 12 lead Holter ECG recording for catheter ablation of PVC.

Methods and results

A total of 16 patients (mean age 52.1±20.8 years, all structurally normal hearts, were enrolled and underwent VIVO mapping as a preparation of their invasive PVC ablation. Pre-ablation PVC burden had a median of 18.7% (IQR; 9.94 – 24.35). All but one patient (with very low PVC burden and epicardial origin) underwent a catheter ablation attempt guided by the 3D non-invasive maps integrated as VTK files in to the EAM. In 13/15 patients, acute elimination of the PVC was achieved which resulted in a PVC burden of <0.1% at 3 months' time. Procedure time amounted to in median 106 minutes (IQR 92.5 – 135.5), whereas in an age- and gender-matched control cohort (2:1) procedure time was significantly longer (145 (123.0 – 190.5).

Conclusion

Ward-based non-invasive 3D mapping (VIVO) of the origin of PVCs in patients with structurally normal hearts successfully guided the invasive ablation procedure and significantly reduced the invasive procedure time, as compared to a contemporary age- and gender-matched control cohort.

Funding Acknowledgement

Type of funding sources: Private company. Main funding source(s): Catheter Precision 3D non-invasive mapping concept
The resuscitation status of implantable cardioverter-defibrillator patients according to electronic health records: are we ignoring the device?
Authors: Aldous R , Dayer M , Furniss G
Published: October 2021

Introduction/Background

The Care Quality Commission (CQC) has recently raised concerns around resuscitation decisions in the UK. In our hospital an early resuscitation decision is made on admission, often by junior doctors, and documented in electronic notes. Concerns have been raised about the veracity of these discussions in patients with implantable cardioverter-defibrillators (ICD's). We investigated resuscitation status as documented on the electronic record for our ICD population.

Methods

The ICD database was interrogated in 2020 for patients under current follow-up. Baseline demographics, hospital admissions over the past 5 years and ICD indications were documented from the electronic hospital records. All patients with an electronic do-not-resuscitate (DNR) flag on the electronic system were recorded, as were any documented resuscitation discussions and ICD deactivations between 2015 and 2020. Any patient deaths were recorded and correlated with resuscitation status and ICD status at the time of death.

Results

Six-hundred and thirty-six patients with ICD's (transvenous, subcutaneous and CRT defibrillators) were identified under follow-up for the study period. The mean age of the population was 68 years old. 251 had an ischaemic cardiomyopathy, 209 had dilated cardiomyopathy, 50 prior ventricular fibrillation or tachycardia, 40 hypertrophic cardiomyopathy, 26 ARVC and the rest a channelopathy, congenital heart disease, sarcoidosis or valvular heart disease.

Thirty-seven of the 636 patients were flagged on the electronic record as being not for resuscitation (5.9%). They had a mean age of 79 and 54% had an ischaemic cardiomyopathy. Of these, only 15 (39%) had their ICD deactivated and only 12 of those at the time of the resuscitation decision (32%). 15 of the 37 (39%) patients made DNR have subsequently died. Six of these (40%) had an active ICD at the time of death.

In the 257 patients who had had a hospital admission in the study period, 34 were made not for resuscitation during the admission (13%) of whom 11 had their ICD deactivated at the time of discussion (32%). Patients with a DNR flag and an “active” ICD were contacted about deactivation of their ICD and offered discussion with a cardiologist or specialist nurse about ICD deactivation. Of these 9/27 (33%) stated that they wanted resuscitation and the alert was removed and the ICD kept on, although 3 subsequently had the device deactivated.

Conclusions

In this study the majority of patients with ICD's who were made not for resuscitation on admission to hospital did not have their ICD therapies switched off, therefore putting them at risk of unnecessary ICD shocks. In addition, one third these patients subsequently chose to be for resuscitation after discussion. These complex decisions would be improved with the early involvement of cardiologists and specialist nurses.

Funding Acknowledgement

Type of funding sources: None.
Validation of leadless atrioventricular synchronous pacing with Holter-ECG: a pilot study
Authors: Briongos Figuero S , Estevez A , Sanchez A , Jimenez S , Gomez E , Jimenez-Candil B , Ortega T , Naranjo M.A , Guimera M.A , Garcia R.T , Munoz-Aguilera R.T
Published: October 2021

Background

The novel MICRA AV leadless pacemaker can provide atrioventricular (AV) synchronous pacing using an accelerometer-based atrial sensing algorithm.

Purpose

To describe the performance of MICRA AV pacemaker in a real-life setting and to determine the agreement between AV synchrony determined by the device counters and AV synchrony obtained by a 24 h ECG Holter test.

Methods

This pilot study included the first ten patients implanted with a MICRA AV leadless pacemaker at our institution. All implants were performed according to standard protocols and under deep sedation. A close follow-up was performed, and atrial sensing parameters were adjusted following AV synchrony given by the device counters. Patients underwent a 24 h ECG Holter test once AV synchrony remained stable for at least two months. The ECG Holter signal was analyzed in a blinded manner by an automatic delineation system based on the wavelet transform (Figure). This algorithm has a sensivity of 98.9% and a positive predictive value of 91.9% to detect p waves. Cardiac cycles were defined as synchronous if a QRS complex followed the P-wave by ≤300 ms, according to MARVEL 2 study criterion. AV synchrony obtained from the 24 h Holter test was compared with AV synchrony extracted from the device counters (AM-VP + AM-VS) during the same 24 h.

Results

From June to November 2020, 10 patients (7 males, mean age 83.5±5.4) were implanted with a MICRA AV leadless pacemaker (5 patients due to complete AV block and 5 patients due to second degree AV block). All devices were implanted after 1 deployment and no major complications appeared. Data related to implant parameters are displayed in Table 1. Device reprogramming was needed in all patients during follow-up. The 24 h ECG Holter monitoring was performed 141.4±45 days after the implant (mean time). Device settings and programming at Holter date is displayed in Table 1. Total ECG recorded time was 210.6 h and 915,488 cardiac cycles were analyzed. The mean percentage of synchronous cardiac cycles was 88.6±8.5% of total cycles while the mean AV synchrony determined by the device counters (AM-VP + AM-VS) during those 24 h was 89.8±5.5%. A good patient to patient correlation between these two measures was found (coefficient of intraclass correlation = 0.72).

Conclusions

We obtained high rates of AV synchrony with MICRA AV leadless pacemaker, in our short-term follow-up pilot study. Manual adjustment of the atrial sensing parameters, guided by the device counters, seems to be useful to obtain an optimal performance.

Funding Acknowledgement

Type of funding sources: None.
Impact of transcatheter aortic valve implantations on temporal trends of pacemaker implantations among French octogenarians: a nation-wide cohort study over the period 2008–2018
Authors: Jacob S , Van Rothen J , Combes S , Errahmani M.Y , Cardin C , Combes N , Albenque J.P , Boveda S
Published: October 2021

Background

The indications for permanent pacemaker implantation (PPMI) are strongly associated with age, with the highest rates for octogenarians (>80 years old). Over the last decade, impact of aging on temporal trends in PPMI rates among octogenarians is questionable. In the 2010's, transcatheter aortic valve implantation (TAVI) has emerged for inoperable or high-risk patients, mainly octogenarians, with an exponential increase over years. PPMI is a common short-term complication after TAVI procedure. Many studies have explored these post-TAVI PPMI in terms of incidence, timing and outcomes of PPMI following TAVI, but there are no data on the impact of TAVI on PPMI temporal trend at a nationwide scale.

Purpose

To evaluate whether PPMI in octogenarians have increased during the last decade, independently from age and sex, on a nationwide scale. Eventually, to estimate the potential contribution of TAVI in PPMI increase in this setting.

Methods

Our study was based on octogenarians from the Echantillon Généraliste de Bénéficiaires, the 1/97 random sample of the French nationwide health insurance claims database. Between 2008 and 2018, we identified de novo PPMI and TAVI with medical procedures codes in the French Common Classification of Medical Procedures (CCAM). Annual incidence rates of PPMI were evaluated between 2008 and 2012 (preTAVI-period). The number of observed PPMI cases, O, in the period 2013–2018 (TAVI-period) was compared with the expected number of PPMI cases, E, calculated by using 2008–2012 incidence rates with age and sex standardization. We then computed the standardized incidence ratio (SIR) of the observed number of PPMI to the expected number of PPMI (O/E), with 95% confidence intervals (CIs). Thereafter, we evaluated the contribution of post-TAVI PPMI in the number of excess cases of PPMI (O-E) for the period 2013–2018.

Results

The population of octogenarians increased from 23,822 in 2008 to 33,752 in 2018. In 2008, 130 PPMI were observed (546/100,000 inhabitants) reaching 228 PPMI (676/100,000) in 2018 with a marked increase in rates from the year 2012. During the period 2013–2018, for all octogenarians, 1242 cases of PPMI were observed, compared with 1171.3 expected cases of PPMI, corresponding to a significant SIR=1.06 (95% CI: 1.01–1.12). For the subpopulation of octogenarians without TAVI, no excess risk was observed with a SIR=1.01 (95% CI: 0.95–1.06). Among the excess cases of PPMI observed in 2013–2018 in all octogenarians, 72% were post-TAVI PPMI.

Conclusion

Based on our study, the number of observed PPMI in octogenarians in period 2013–2018 is 6% higher than the number we would expect. Nearly three-quarter of these excess cases are attributable to TAVI complication.

Funding Acknowledgement

Type of funding sources: None.
Ethnic variation in implantable cardioverter defibrillator implant trends in New Zealand 2005–2019
Authors: Foo F.S , Lee M , Stiles M.K , Poppe K.K , Jackson R , Kerr A.J
Published: October 2021

Background

Implantable cardioverter defibrillator (ICD) implant rates in New Zealand (NZ) have increased significantly in recent years. Previous studies in NZ have demonstrated that Māori and Pacific patients had higher rates of ischaemic heart disease compared to other ethnicities. Ethnic variation in ICD implant rates have been reported internationally, but whether this trend exists in NZ is unclear.

Purpose

This paper aims to provide the first analysis of new ICD implants by ethnicity over an extended time period.

Methods

All patients who received a new ICD implant were identified for the period of 1st January 2005 to 31st December 2019 using the National Minimum Datasets, which collects information on all public hospital admissions in NZ. Ethnicity prioritisation was performed in the following order: Māori, Pacific, Asian and European. New ICD implant rates were analysed by ethnicity and age-groups.

Results

A total of 5,514 new ICDs were implanted over the study period. New ICD implant rates increased by 137%, from 41.4/million in 2005 to 98.2/million in 2019, at an average of 5.4%/year (p<0.01). Over the study period, the highest age-standardised implant rates were in Māori, followed by Pacific, European and Asian ethnicities. The largest increase was seen in Pacific patients at 8.9%/year (p<0.01), followed by Māori and Asian patients at 4.7%/year (p<0.01) and 4.3%/year (p<0.01), respectively. In European patients, ICD implant rates initially increased by 10.3%/year (p<0.01) between 2005 to 2012, but subsequently plateaued at −0.4%/year (p=0.71) between 2012 to 2019. By 2019, the age-standardised implant rates in Māori, Pacific and European patients were 3 to 4 times higher than Asian patients (Figure 1).

In the age groups of <39, 40–59, 60–69 and 70–79 years, Māori and Pacific patients had higher implant rates through most of the study period. Asian patients consistently had the lowest new ICD implant rates across all age groups. The substantially higher age-specific implant rates in the age groups of 40–59 years and 60–69 years in Māori and Pacific patients resulted in higher overall age-standardised implant rates as compared to Asian and European ethnicities.

Conclusion

There is marked ethnic variation in ICD implant rates in NZ. Implant rates have increased in ethnic minorities but have plateaued in European patients in the past 7 years. The continued difference in implant rates across ethnicities warrants further investigation.

Funding Acknowledgement

Type of funding sources: None.